KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Total Liabilities (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Total Liabilities for 16 consecutive years, with -$48.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Liabilities fell 102.87% to -$48.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$48.8 million, a 102.87% decrease, with the full-year FY2025 number at -$48.8 million, down 102.87% from a year prior.
  • Total Liabilities was -$48.8 million for Q4 2025 at Halozyme Therapeutics, down from $1.7 billion in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $1.8 billion in Q3 2022 to a low of -$293.2 million in Q2 2022.
  • A 5-year average of $1.1 billion and a median of $1.6 billion in 2023 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: crashed 132.35% in 2022, then soared 727.69% in 2023.
  • Halozyme Therapeutics' Total Liabilities stood at $907.5 million in 2021, then skyrocketed by 84.22% to $1.7 billion in 2022, then decreased by 1.33% to $1.6 billion in 2023, then increased by 3.04% to $1.7 billion in 2024, then plummeted by 102.87% to -$48.8 million in 2025.
  • Per Business Quant, the three most recent readings for HALO's Total Liabilities are -$48.8 million (Q4 2025), $1.7 billion (Q3 2025), and $1.7 billion (Q2 2025).